Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Studies from Baylor College of Medicine, College of Medicine further understanding of breast cancer
June 26th, 2008
" Tumorigenic breast cancer cells that express high levels of CD44 and low or undetectable levels of CD24 (CD44(+)/CD24(-/low)) may be resistant to chemotherapy and therefore responsible for cancer relapse. These tumorigenic cancer cells can be isolated from breast cancer biopsies and propagated as mammospheres in vitro," investigators in the United States report. "In this study, we aimed to test directly in human breast cancers the effect of conventional chemotherapy or lapatinib (an epidermal growth factor receptor [EGFR]/HER2 pathway inhibitor) on this tumorigenic CD44(+) and CD24(-/low) cell population. Paired breast cancer core biopsies were obtained from patients...
Source: Women's Health Weekly (2008-06-26)
|
